PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 6 months ago Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025 Phase II Trial Head And Neck Cancer Cancer Vaccine Transgene TG4050
BRIEF published on 05/14/2024 at 17:50, 1 year 6 months ago Transgene Announces Positive Q1 2024 Update and Future Clinical Milestones Clinical Trials Financial Update Cancer Immunotherapy Transgene TG4050
PRESS RELEASE published on 05/14/2024 at 17:45, 1 year 6 months ago Transgene provides business and financial update for Q1 2024 Transgene provides business and financial update for Q1 2024, including promising Phase I data on TG4050 and upcoming clinical data expectations on TG4001, TG6050, and BT-001 in H2 2024 Clinical Data Q1 2024 Financial Update Transgene TG4050
Published on 12/05/2025 at 02:35, 7 hours 14 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 49 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 44 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 49 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:30, 19 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 44 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 1 hour 4 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 49 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 4 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 5 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
